Everolimus Safety Profile in Liver Transplant Recipients With 3-Year Exposure in the H2304 Core and Extension Study.

被引：0
|
作者：
Saliba, F. [1 ]
Rogiers, X. [1 ]
Chapman, W. [1 ]
Caicedo, L. [1 ]
Alsina, A. [1 ]
Teperman, L. [1 ]
Junge, G. [1 ]
Rauer, B. [1 ]
Dong, G. [1 ]
De Simone, P. [1 ]
机构：
[1] H2304E1 Study Grp, Villejuif, France
来源：
LIVER TRANSPLANTATION | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P-310
引用
收藏
页码：S247 / S248
页数：2
相关论文
共 50 条
  • [31] Impact of Everolimus, an mTORC1 Inhibitor, on Hepatocellular Carcinoma Recurrence After Liver Transplantation: Results from the H2304 Study
    Junge, Guido
    Saliba, Faouzi
    De Simone, Paolo
    Fischer, Lutz
    Dong, Gaohong
    Speziale, Antonio
    Fung, John
    TRANSPLANTATION, 2015, 99 : 90 - 91
  • [32] Association between Everolimus Trough Levels, Onset of Related Adverse Events, and Treatment Discontinuation after Liver Transplantation: 24-Month Results from the H2304 Study.
    Fung, J.
    Saliba, F.
    Schlitt, H.
    Junge, G.
    McCague, K.
    Patel, D.
    Charlton, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 627 - 628
  • [33] IMPACT OF EVEROLIMUS, AN MTORC1 INHIBITOR, ON HEPATOCELLULAR CARCINOMA RECURRENCE AFTER LIVER TRANSPLANTATION: RESULTS FROM THE H2304 STUDY
    Duvoux, C.
    Durand, F.
    Neau-Cransac, M.
    Hardwigsen, J.
    Pageaux, G.
    Di Giambattista, F.
    Saliba, F.
    TRANSPLANT INTERNATIONAL, 2016, 29 : 5 - 5
  • [34] The H2304E1 Study: Efficacy and Safety of Everolimus With Reduced Tacrolimus Versus Standard Tacrolimus in De Novo Liver Transplant Recipients at 36 Months.
    De Simone, P.
    Kaiser, G. M.
    De Carlis, L.
    Metselaar, H. J.
    Duvoux, C.
    Nevens, F.
    Fischer, L.
    Fung, J.
    Dong, G.
    Rauer, B.
    Junge, G.
    Saliba, F.
    LIVER TRANSPLANTATION, 2014, 20 : S106 - S106
  • [35] Efficacy and Safety of Everolimus in De Novo Liver Transplant Recipients-12 Month Results of a Randomized, Multicenter Study.
    Fung, J.
    Nevens, F.
    De Carlis, L.
    Metselaar, H. J.
    Beckebaum, S.
    Saliba, F.
    Jonas, S.
    Sudan, D.
    Fischer, L.
    Duvoux, C.
    Chavin, K. D.
    Jiang, H.
    Hexham, J. M.
    Junge, G.
    De Simone, P.
    LIVER TRANSPLANTATION, 2012, 18 : S109 - S110
  • [36] 3-Year Safety Profile of Belatacept in Kidney Transplant Recipients from the BENEFIT and BENEFIT-EXT Studies
    Larsen, C.
    Grinyo, J.
    Pestana, J. M.
    Vanrenterghem, Y.
    Vincenti, F.
    Dong, Y.
    Thomas, D.
    Charpentier, B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 99 - 100
  • [37] 3-YEAR SAFETY PROFILE OF BELATACEPT IN KIDNEY TRANSPLANT RECIPIENTS FROM THE BENEFIT AND BENEFIT-EXT STUDIES
    Larsen, C.
    Grinyo, J.
    Medina Pestana, J.
    Vanrenterghem, Y.
    Vincenti, F.
    Dong, Y.
    Thomas, D.
    Charpentier, B.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 51 - 51
  • [38] 3-YEAR SAFETY PROFILE OF BELATACEPT IN KIDNEY TRANSPLANT RECIPIENTS FROM THE BENEFIT AND BENEFIT-EXT STUDIES
    Charpentier, Bernard
    Grinyo, Josep
    Medina Pestana, Jose O.
    Vanrenterghem, Yves
    Vincenti, Flavio
    Dong, Yuping
    Thomas, Dolca
    Larsen, Christian P.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 68 - 69
  • [39] Everolimus with Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplant Recipients: Efficacy and Safety Outcomes from the TRANSFORM Study.
    Chadban, S.
    Mulgaonkar, S.
    Pascual, J.
    Tedesco, H.
    Berger, S.
    Qazi, Y.
    Legendre, C.
    Basic-Jukic, N.
    Bernhardt, P.
    Vincenti, F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 475 - 475
  • [40] A Study on the Safety and Effectiveness of Everolimus in Liver Transplant Recipients for Pancreatic Neuroendocrine Tumors.
    Zhao, Xu
    Vanatta, Jason
    Eason, James
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 103 - 103
12345